收费全文 | 12142篇 |
免费 | 789篇 |
国内免费 | 38篇 |
耳鼻咽喉 | 90篇 |
儿科学 | 368篇 |
妇产科学 | 338篇 |
基础医学 | 1743篇 |
口腔科学 | 376篇 |
临床医学 | 1713篇 |
内科学 | 2010篇 |
皮肤病学 | 295篇 |
神经病学 | 1063篇 |
特种医学 | 266篇 |
外科学 | 1124篇 |
综合类 | 119篇 |
一般理论 | 12篇 |
预防医学 | 1643篇 |
眼科学 | 156篇 |
药学 | 769篇 |
1篇 | |
中国医学 | 25篇 |
肿瘤学 | 858篇 |
2023年 | 65篇 |
2022年 | 146篇 |
2021年 | 280篇 |
2020年 | 208篇 |
2019年 | 274篇 |
2018年 | 357篇 |
2017年 | 228篇 |
2016年 | 304篇 |
2015年 | 320篇 |
2014年 | 455篇 |
2013年 | 634篇 |
2012年 | 951篇 |
2011年 | 982篇 |
2010年 | 556篇 |
2009年 | 522篇 |
2008年 | 859篇 |
2007年 | 878篇 |
2006年 | 832篇 |
2005年 | 779篇 |
2004年 | 714篇 |
2003年 | 585篇 |
2002年 | 605篇 |
2001年 | 121篇 |
2000年 | 81篇 |
1999年 | 116篇 |
1998年 | 115篇 |
1997年 | 97篇 |
1996年 | 76篇 |
1995年 | 73篇 |
1994年 | 54篇 |
1993年 | 63篇 |
1992年 | 52篇 |
1991年 | 42篇 |
1990年 | 46篇 |
1989年 | 55篇 |
1988年 | 47篇 |
1987年 | 35篇 |
1986年 | 32篇 |
1985年 | 32篇 |
1984年 | 29篇 |
1983年 | 32篇 |
1982年 | 25篇 |
1981年 | 33篇 |
1980年 | 30篇 |
1979年 | 24篇 |
1978年 | 16篇 |
1977年 | 13篇 |
1974年 | 8篇 |
1973年 | 8篇 |
1972年 | 8篇 |
Background
Bone mineral density (BMD) has been found to improve after parathyroidectomy (PTX) in patients with primary hyperparathyroidism. There are few data on the effect of PTX on BMD in normocalcemic and normohormonal primary hyperparathyroidism.Methods
A retrospective analysis of 92 primary hyperparathyroidism patients who underwent PTX between 2004 and 2012 with pre- and post-PTX dual-energy x-ray absorptiometry was performed. Within-person changes in BMD pre- and post-PTX were analyzed using log linear mixed models, stratified by biochemical status.Results
Bone mineral density increased post-PTX in the whole cohort at the lumbar spine (+2.5%), femoral neck (+2.1%), and total hip (+1.9%) and decreased at the one-third radius (–0.9%). On comparison of BMD changes by profile, BMD increased in those with the typical profile at the lumbar spine (3.2%), femoral neck (2.9%), and total hip (2.9%) but declined at the one-third radius (–1.5%). In contrast, BMD improved only at the femoral neck (4.3%) in the normohormonal group and did not change at any site in the normocalcemic group. The typical group had a greater increase in BMD over time at the femoral neck and total hip compared with normocalcemic patients.Conclusion
Our results indicate that the skeletal benefit of PTX was attenuated in normocalcemic and normohormonal patients, suggesting that skeletal changes after PTX may depend on biochemical profile. 相似文献Background
Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.Patients and Methods
We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.Results
Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.Conclusions
FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients. 相似文献Design: A mixed-methods design, applying the Schwartz and Sprangers response shift (RS) model. RS is a cognitive process wherein, in response to a change in health status, individuals change internal standards, values, or conceptualization of QOL
Setting: Community-dwelling participants who receive medical treatment at a major Midwestern medical system and nearby Veterans’ Affairs hospital.
Participants: A purposive sample of participants with SCI (N?=?40) completed semi-structured interviews and accompanying quantitative measures.
Interventions: Not applicable.
Outcome Measures: Qualitative data were analyzed using content analysis to identify themes. Analysis of variance were performed to detect differences based on themes and QOL, well-being, and demographic and injury characteristics.
Results: Four RS themes were identified, capturing the range of participant perceptions of QOL. The themes ranged from complete RS, indicating active engagement in maintaining QOL, to awareness and comparisons redefining QOL, to a relative lack of RS. Average QOL ratings differed as a function of response shift themes. PROMIS Global Health, Anxiety, and Depression also differed as a function of RS themes.
Conclusion: The RS model contextualizes differences in QOL definitions, appraisals, and adaptations in a way standardized QOL measures alone do not. 相似文献